The UPV/EHU and the pharmaceutical company Janssen have launched a training and research space specializing in Pharmacology at the University of the Basque Country. The so-called ‘Aula Janssen’, which is promoted by the Department of Health, was presented this Wednesday but has already started a few months ago with the aim of advancing in the transformation of health and health care, as well as analyzing current needs and generate solutions to emerging challenges.
The initiative, framed in the network of Chairs of Innovation, a pioneering action that the Belgian laboratory has launched with five other Spanish universities to address issues related to Medicine from different perspectives, aims to contribute to shaping the biomedical innovation hub that Euskadi aspires and that is woven through public-private collaborations such as this one that “are providing such good results to our country”, pointed out the Minister of Health Gotzone Sagardui. “It will bring talent to our environment and open us up to the world. If anyone still had any doubts, the pandemic that we have had to live through and that still continues, has highlighted even more the importance of investing in science, research, innovation, in short, in the promotion of knowledge«, has defended the maximum responsible for health in Euskadi.
Although the company belonging to the Johnson group
This allows the approach of therapies to the peculiarities of each person. This is what is known as personalized medicine, which seeks to adapt treatments to the profiles of each patient. “The evolution towards a values-based health system requires professionals to learn to think differently about their role within cross-functional teams, about what constitutes an effective health solution, and about the importance of measuring the health outcomes that matter most. to the patients. The University can and must become the engine of this learning, as it has the responsibility of instructing the professionals of the future in their initial training steps”, said this professional who directs a research group in Neuropsychopharmacology, attached to the Department of Pharmacology of the UPV/EHU. Its activities focus on the study of the biological bases of mental illnesses such as schizophrenia and depression, and the development of effective and safe treatments for them.
As he explained, the Janssen Classroom has already begun to hold some activities such as debates with professionals specialized in serious trauma or a day dedicated to patients with psychosis and is preparing some research, as well as other activities. For her part, the rector of the center has underlined the “clear commitment to the scientific staff of the UPV / EHU” and has recalled the improvement in humanization in health care. Meanwhile, Luis Díaz-Rubio, the general director of Janssen Iberia, has assured that “pharmaceutical innovation” plays a relevant role in society, since “74% of the gains in years of life expectancy are related in a way directly” with developments in this area.
7
